Latest Pharmaceuticals News

Opthea has completed the final patient visit in its pivotal COAST Phase 3 trial evaluating sozinibercept combined with aflibercept for wet AMD, with topline results expected early Q2 2025.

Neurizon Therapeutics reported a sharp rise in half-year losses to $7.28 million but marked significant progress with its lead drug NUZ-001 entering a major ALS clinical trial and securing critical regulatory designations.

PYC Therapeutics has launched a A$145.8 million pro-rata accelerated non-renounceable entitlement offer to fund late-stage clinical trials across its pipeline targeting rare diseases with high unmet needs. The capital raise aims to extend the company’s cash runway beyond FY27, supporting four drug candidates through critical human safety and efficacy milestones.

Recce Pharmaceuticals reports strong Phase II results for its RECCE® 327 topical gel, achieving a 93% efficacy rate in treating serious skin infections and setting the stage for accelerated Phase 3 trials.

Avecho Biotechnology has responded to an ASX price query, confirming no undisclosed information exists to explain recent trading spikes, while highlighting market speculation linked to its Phase III CBD insomnia trial.

Recce Pharmaceuticals has temporarily paused trading of its securities, signaling a potentially significant development pending further disclosure.

Telix Pharmaceuticals has gained UK MHRA approval for Illuccix, its advanced prostate cancer PET imaging agent, promising to alleviate supply shortages and improve diagnostic accuracy across the UK.

Sigma Healthcare has completed its acquisition of Chemist Warehouse, issuing new shares and cash to former shareholders and appointing a refreshed board to steer the merged entity forward.

Island Pharmaceuticals has successfully completed patient dosing in the Phase 2b therapeutic arm of its PROTECT clinical trial for ISLA-101, targeting dengue fever treatment. High-level results are expected within two months, potentially advancing a significant antiviral candidate.

Clarity Pharmaceuticals has expanded its breast cancer pipeline by introducing 64/67Cu-SAR-trastuzumab, supported by promising pre-clinical data and a new supply agreement for trastuzumab, aiming to address the unmet needs in HER2-positive breast cancer treatment.

CSL Limited has announced a USD 1.30 per share dividend for the half-year ending December 2024, marking a steady return for investors despite the payout being fully unfranked.

CSL Limited reported a solid half-year performance with 5% revenue growth and a 7% rise in net profit, driven by strong demand in its Behring and Vifor segments despite challenges in Seqirus. The company reaffirmed its full-year NPATA guidance of 10-13%, signaling confidence in its operational momentum.